저침습수술(MIS) 시장은 2024년 814억 2,000만 달러로 평가되었습니다. 2025년에 918억 6,000만 달러에 이르고, CAGR13.02%로 성장하여 2030년에는 1,697억 5,000만 달러에 달할 것으로 예측됩니다.
| 주요 시장 통계 | |
|---|---|
| 기준 연도 : 2024년 | 814억 2,000만 달러 |
| 추정 연도 : 2025년 | 918억 6,000만 달러 |
| 예측 연도 : 2030년 | 1,697억 5,000만 달러 |
| CAGR(%) | 13.02% |
저침습수술(MIS)의 상황은 기술적 혁신과 임상 프로토콜의 진화에 따라 빠르게 변화하고 있습니다. 외과 의사, 의료 기관, 의료기기 제조업체는 현재 수술의 정확성을 높이고 환자의 외상을 줄이겠다는 공통의 목표 아래 모이고 있습니다. 전통적인 개복 수술이 열쇠구멍 수술로 대체됨에 따라 임상의는 내시경, 첨단 에너지 공급 시스템, 고화질 비디오 플랫폼을 채택하여 시각화 및 제어를 최적화하고 있습니다. 이러한 배경에는 빠른 회복을 원하는 환자들의 선호도 증가, 의료 예산의 압박, 병원 처리 능력에 대한 압박 증가 등의 요인이 복합적으로 작용하여 전 세계적으로 저침습적 접근법의 채택이 가속화되고 있습니다.
영상 양식, 기기 설계 및 시술 워크플로우의 혁신은 더 높은 정확도와 환자 결과 개선을 약속하는 최소침습적 방법의 새로운 시대를 열었습니다. 멀티스코프 내시경과 첨단 에너지 장비의 보급은 기존의 장벽을 넘어 해부학적으로 복잡하고 이전에는 도달할 수 없었던 영역에 대한 접근을 가능하게 했습니다. 이와 함께, 실시간 데이터 오버레이와 증강현실 플랫폼의 통합은 외과 의사의 상황 인식을 향상시켜 보다 안전한 개입을 촉진하고 시행착오에 대한 의존도를 낮추었습니다.
2025년까지 시행되는 미국의 무역 관세의 누적 효과는 저침습수술(MIS) 장비 공급망에 새로운 복잡성을 가져오고 있습니다. 첨단 내시경, 에너지 기반 발전기, 로봇 모듈 부품에 대한 수입 관세는 세계 조달 네트워크에 의존하는 제조업체의 비용을 상승시키고 있습니다. 일부 기업들은 경쟁력 있는 가격 책정을 유지하기 위해 이러한 추가 비용의 일부를 흡수하고 있지만, 조달 주기가 길어지거나 공급업체 계약 재협상을 통해 더 광범위한 생태계가 압박을 받고 있습니다.
시장 세분화 분석 결과, 내시경, 에너지 장비, 복강경 장비, 비디오 플랫폼을 중심으로 한 장비 포트폴리오가 각각 고유한 성장 촉매 역할을 하는 것으로 나타났습니다. 복강경 기기 카테고리에서는 디스셉터, 그래퍼, 리트랙터, 가위, 트로커 등의 기기가 재료 과학과 인체공학의 꾸준한 진화를 통해 외과 의사의 편안함과 수술 효율을 모두 향상시키고 있습니다. 이러한 도구가 점점 더 복잡한 케이스 구성에 적응함에 따라 첨단 영상 처리 시스템 및 에너지 공급 시스템과의 통합은 하드웨어 설계와 임상 워크플로우 간의 중요한 상호 작용을 더욱 강조하고 있습니다.
저침습수술(MIS)의 지역별 역학은 의료 인프라, 상환 모델, 인구 동향의 영향을 받아 채택률의 편차를 반영하고 있습니다. 미국 대륙에서는 병원 개축 및 외래 시설 확장을 위한 활발한 설비투자가 첨단 플랫폼의 강력한 도입을 뒷받침하고 있습니다. 또한, 가치 기반 의료를 지향하는 정책적 변화로 인해 재원일수를 단축하고 수술 후 합병증을 최소화하는 중재가 장려되고 있어 저침습적 시술에 대한 수요가 더욱 증가하고 있습니다.
저침습수술(MIS) 분야의 주요 기업들은 시장에서의 포지셔닝을 강화하고 기술 혁신을 가속화하기 위해 다각적인 전략을 추구해 왔습니다. 세계적인 장비 제조업체들은 외과 의사의 워크플로우를 개선하는 종합적인 시술 제품군을 제공하기 위해 영상 처리, 에너지 공급, 내비게이션 기능을 결합한 크로스 플랫폼 통합을 시작했습니다. 로봇 전문가와 에너지 장비 혁신가를 전략적으로 인수하여 제품 로드맵을 강화하고, 학술 센터와의 협력 파트너십을 통해 초기 단계의 검증 및 외과 의사 교육 프로그램을 촉진하고 있습니다.
변화하는 규제 환경을 극복하기 위해 업계 리더들은 규제 당국과의 관계를 우선시하여 엄격한 안전 표준을 보장하고 새로운 기기의 승인 경로를 단축해야 합니다. 규제 당국과 협력하는 전문 팀을 구성하여 임상시험 설계를 간소화하고 시장 진입을 가속화할 수 있습니다. 이와 함께, 지불 기관과 파트너십을 맺고 가치 기반 상환 프레임워크를 개발함으로써, 저침습적 치료의 도입에 대한 경제적 인센티브를 강화하여 의료 서비스 제공업체들 사이에서 더 폭넓게 수용될 수 있도록할 것입니다.
이 보고서는 거시적 차원의 트렌드와 각 분야의 세부적인 뉘앙스를 파악하기 위해 고안된 엄격한 다층적 조사방법을 통해 도출된 통찰력을 통합한 보고서입니다. 1차 조사에서는 외래수술센터(ASC) 및 병원 최종 사용자, 조달 전문가, 임상 오피니언 리더 등 KOL(Key Opinion Leader)를 대상으로 심층 인터뷰를 진행했습니다. 이러한 직접적인 관점은 새로운 기기 선호도와 절차의 워크플로우에 대한 중요한 검증을 제공했습니다.
결론적으로, 저침습수술(MIS) 분야는 기술적 창의성과 변화하는 의료 요구의 교차점에 서 있습니다. 내시경, 에너지 공급 시스템, 복강경 수술 기구, 비디오 장비와 같은 장비 혁신은 수술의 가능성을 계속 재정의하고 있으며, 로봇 지원은 인체공학적이고 정밀한 한계를 넓혀가고 있습니다. 동시에 관세 압력과 지역 격차는 적극적인 공급망 전략과 지역 밀착형 시장 접근의 필요성을 강조하고 있습니다.
The Minimally Invasive Surgery Market was valued at USD 81.42 billion in 2024 and is projected to grow to USD 91.86 billion in 2025, with a CAGR of 13.02%, reaching USD 169.75 billion by 2030.
| KEY MARKET STATISTICS | |
|---|---|
| Base Year [2024] | USD 81.42 billion |
| Estimated Year [2025] | USD 91.86 billion |
| Forecast Year [2030] | USD 169.75 billion |
| CAGR (%) | 13.02% |
The landscape of minimally invasive surgery has undergone a rapid transformation driven by technological breakthroughs and evolving clinical protocols. Surgeons, healthcare institutions, and medical device manufacturers now converge around a shared goal of reducing patient trauma while enhancing procedural precision. As traditional open procedures give way to keyhole interventions, clinicians have embraced endoscopes, advanced energy delivery systems, and high-definition video platforms to optimize visualization and control. Against this backdrop, a confluence of factors-rising patient preference for faster recovery, tightening healthcare budgets, and mounting pressure on hospital throughput-has accelerated the adoption of minimally invasive approaches worldwide.
Moreover, the convergence of digital innovation and surgical technique has redefined the operating room. Cloud-based data analytics, AI-driven image guidance, and telecollaboration tools have enhanced preoperative planning and intraoperative decision making. Concurrently, educational institutions and professional societies have prioritized simulation-based training and credentialing programs to equip the next generation of surgeons with the skills required for complex minimally invasive procedures. Together, these dynamics have reshaped care pathways, elevating patient satisfaction, reducing length of stay, and creating a fertile ground for continued innovation across devices, robotics, and software ecosystems.
Innovations in imaging modalities, instrument design, and procedural workflows have ushered in a new era of minimally invasive methodologies that promise greater precision and improved patient outcomes. The proliferation of multi-spectrum endoscopes and advanced energy devices has transcended traditional barriers, enabling access to anatomically complex and previously unreachable regions. In parallel, the integration of real-time data overlays and augmented reality platforms has bolstered surgeons' situational awareness, fostering safer interventions and reducing reliance on trial-and-error techniques.
Furthermore, the rise of robotic-assisted platforms marks a transformative shift in how surgical teams collaborate and execute intricate procedures. Multiarm systems deliver enhanced dexterity and tremor filtration, allowing for micro-precision that surpasses human steadiness. At the same time, singlearm robotic modules are democratizing access by offering cost-efficient solutions for community hospitals and outpatient settings. This dual approach to automation underscores a broader trend toward modular, interoperable systems that can adapt to diverse case types across cardiovascular, gynecological, urological, and general surgical specialties.
The cumulative effect of U.S. trade tariffs implemented by 2025 has introduced new complexities into the supply chain for minimally invasive surgical equipment. Import duties on components for advanced endoscopes, energy-based generators, and robotic modules have elevated costs for manufacturers relying on global sourcing networks. Although some companies have absorbed a portion of these additional expenses to maintain competitive pricing, the broader ecosystem has felt pressure through elongated procurement cycles and renegotiated vendor agreements.
Consequently, healthcare providers have recalibrated purchasing strategies to mitigate cost increases. Some institutions have prioritized domestically produced instruments, while others have sought long-term contracts to lock in pricing and guarantee supply continuity. Despite these headwinds, the drive toward procedural efficiency and clinical efficacy remains undiminished. As a result, manufacturers are exploring strategic partnerships and alternative component suppliers to navigate tariff-induced margins and preserve the trajectory of minimally invasive innovation.
Analysis of market segmentation reveals that device portfolios centered on endoscopes, energy devices, laparoscopic instruments, and video platforms each exhibit unique growth catalysts. Within the laparoscopic instruments category, instruments such as dissectors, graspers, retractors, scissors, and trocars demonstrate steady evolution in material science and ergonomics, enhancing both surgeon comfort and procedural efficiency. As these tools adapt to increasingly complex case mixes, their integration with advanced imaging and energy delivery systems further underscores the critical interplay between hardware design and clinical workflow.
Segmentation by technology highlights the contrast between manual approaches and robotic-assisted ecosystems. Manual instruments continue to benefit from incremental improvements in user interface and haptic feedback, supporting high-volume ambulatory surgery center procedures. Meanwhile, robotic-assisted solutions-spanning both multiarm and singlearm configurations-are enabling greater procedural versatility, particularly in intricate cardiovascular, gynecological, and urological interventions. Application-based insights underscore strong uptake in general surgery contexts, where standardization of protocols accelerates adoption, complemented by growing interest in niche procedures across oncology and endocrine specialties. Finally, understanding the end user landscape reveals that ambulatory surgery centers focus on high-throughput, cost-effective procedures, while hospitals across primary, secondary, and tertiary care tiers demand comprehensive systems capable of supporting complex case portfolios and integrated care pathways.
Regional dynamics in minimally invasive surgery reflect disparate adoption rates influenced by healthcare infrastructure, reimbursement models, and demographic trends. In the Americas, robust capital investment in hospital renovation and outpatient facility expansion has underpinned strong uptake of advanced platforms. Additionally, policy shifts aimed at value-based care have incentivized interventions that reduce length of stay and minimize postoperative complications, further fueling demand for minimally invasive procedures.
Meanwhile, Europe, the Middle East and Africa exhibit heterogeneous growth pathways. Western Europe's mature healthcare systems continue to adopt incremental device innovations, whereas emerging markets in the Middle East are investing in center-of-excellence programs to establish surgical hubs of regional importance. Across Africa, capacity constraints and workforce training gaps present challenges, yet targeted public-private collaborations are beginning to introduce minimally invasive techniques in tertiary care facilities. In the Asia-Pacific region, expanding healthcare budgets, government initiatives to modernize public hospitals, and rising medical tourism converge to create a fertile environment for new equipment launches and localized manufacturing ventures.
Leading players in the minimally invasive surgery domain have pursued multifaceted strategies to reinforce their market positioning and accelerate innovation. Global device manufacturers have launched cross-platform integrations that combine imaging, energy delivery, and navigation capabilities, aiming to deliver comprehensive procedural suites that enhance surgeon workflow. Strategic acquisitions of robotics specialists and energy device innovators have bolstered their product roadmaps, while collaborative partnerships with academic centers facilitate early-stage validation and surgeon training programs.
At the same time, pure-play robotics developers continue to differentiate through next-generation platforms that prioritize modular design and artificial intelligence-driven assistance. By forging alliances with software firms and cloud-based analytics providers, these emerging entrants are redefining the standard for intraoperative decision support. Meanwhile, specialty companies focused on advanced optics and ergonomic instrument handles leverage niche expertise to influence broader system designs. Collectively, these competitive moves underscore a market characterized by both consolidation among incumbents and disruptive leaps from agile innovators.
To navigate the evolving landscape, industry leaders should prioritize regulatory engagement that expedites approval pathways for novel devices while ensuring rigorous safety standards. Establishing dedicated teams to collaborate with regulatory bodies can streamline clinical trial design and accelerate market entry. In parallel, forging partnerships with payer organizations to develop value-based reimbursement frameworks will solidify economic incentives for minimally invasive adoption and drive broader acceptance among healthcare providers.
Investment in modular robotic architectures that accommodate both multiarm and singlearm applications can unlock new revenue streams across diverse care settings. By offering scalable platforms, manufacturers can tailor solutions to the procedural requirements of ambulatory surgery centers, community hospitals, and tertiary care facilities. Moreover, integrating telecollaboration and remote monitoring functionalities will support surgeon training, postoperative follow-up, and cross-institutional best practice sharing.
Supply chain resilience must also be addressed through strategic sourcing and nearshoring initiatives that mitigate tariff-induced volatility. Building local manufacturing partnerships and diversifying component suppliers will enhance cost stability and ensure uninterrupted access to critical instrumentation. Finally, leveraging real-world evidence and data analytics to demonstrate clinical outcomes and cost savings will strengthen market positioning and facilitate payor negotiations, paving the way for sustained growth in the minimally invasive surgery arena.
This report synthesizes insights drawn from a rigorous multi-tiered research methodology designed to capture both macro-level trends and granular sector nuances. Primary research encompassed in-depth interviews with key opinion leaders, including end users in ambulatory surgery centers and hospitals, procurement specialists, and clinical thought leaders. These firsthand perspectives provided critical validation for emerging device preferences and procedural workflows.
Complementing this, secondary research involved systematic examination of published literature, regulatory filings, and white papers on surgical robotics, energy devices, and advanced imaging systems. Proprietary databases served to cross-reference OEM announcements, partnership disclosures, and clinical trial registries. The resulting analysis was then triangulated through expert workshops and peer reviews to ensure robustness and impartiality, yielding a comprehensive framework that supports strategic decision making.
In conclusion, the minimally invasive surgery sector stands at the intersection of technological ingenuity and shifting healthcare imperatives. Device innovation across endoscopes, energy delivery systems, laparoscopic instruments, and video equipment continues to redefine procedural possibilities, while robotic assistance expands ergonomic and precision frontiers. Simultaneously, tariff pressures and regional disparities underscore the need for proactive supply chain strategies and localized market approaches.
Looking ahead, the successful deployment of minimally invasive solutions will hinge on cross-industry collaboration, regulatory foresight, and data-driven value demonstration. By aligning product development with clinician needs, forging payer partnerships, and embracing modular, interoperable platforms, stakeholders can navigate complexity and capture long-term growth opportunities. This executive summary provides a strategic blueprint for informed decision making in a rapidly evolving surgical environment.